UPDATE SURVIVAL OF PHASE 1B CLINICAL TRIAL OF HX008, A NOVEL ANTI-PD-1 MONOCLONAL ANTIBODY, COMBINED WITH GEMCITABINE AND CISPLATIN IN THE FIRST-LINE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER